Executive Order 14398 Bans DEI Activities by Federal Contractors — FQHCs as HRSA Grantees Face Compliance Risk
Trump signed EO 14398 prohibiting 'racially discriminatory DEI activities' by federal contractors and grantees. FQHCs receiving HRSA Section 330 grants face compliance deadlines: contract clauses (30 days), FAR guidance (May 25), agency reports (July 24).
The EO creates direct tension with CLAS Standards requiring culturally concordant workforce recruitment. Violations can trigger contract termination, debarment, and False Claims Act liability.
FQHCs with workforce diversity programs, culturally concordant hiring, or race/ethnicity-targeted training need compliance review.
Key takeaways
- FQHC CLAS Standards vs EO 14398: culturally concordant hiring now legally risky
- FAR guidance deadline May 25 — FQHCs should review HR policies now
- Violations can trigger debarment, contract termination, and FCA liability
Primary source
The Employer Report / Sullivan & CromwellSource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
FQHC Talent. (2026, March 26). Executive Order 14398 Bans DEI Activities by Federal Contractors — FQHCs as HRSA Grantees Face Compliance Risk. Primary source: The Employer Report / Sullivan & Cromwell. Retrieved July 28, 2026, from https://www.fqhctalent.com/intel/eo-14398-dei-restrictions-federal-contractors-fqhc
More in Legislation
Jul 24
HHS strips disparate-impact liability out of its Title VI regulations — final rule, effective the day it published, no comment period; 45 CFR part 80 binds every Section 330 grantee
Jul 22
Arkansas AG sues 13 drugmakers + a data firm over 340B — the first time a state goes on OFFENSE under its own 340B shield law, with the state health-center association standing beside him
Jul 16
CY2027 Physician Fee Schedule Proposed Rule Lands — CMS Proposes the FQHC PPS Base Rate Rise to $212.91 (+2.5%), Comments Close September 14
Jul 1
8th Circuit Rejects Novartis's Bid to Block Missouri's 340B Contract-Pharmacy Law — Another State Shield Survives a Manufacturer Challenge